Abstract
Antibacterial and antifungal activity of 10-(diphenylmethylene)-4-azatricyclo[5.2.1.02,6]dec-8-ene-3,5-dione derivatives were examined by the disc-diffusion method (growth inhibition zone diameter in agar medium). The MIC’s for the most active agents were determined. Title compounds were also evaluated in vitro against representatives of different virus classes. Most of the tested compounds exhibit activity against CVB-2 virus.
[1] Furse K.E., Lybrand T.P., Three-dimensional models for beta-adrenergic receptor complexes with agonists and antagonists, J. Med. Chem., 2003, 46, 4450–4462 http://dx.doi.org/10.1021/jm030143710.1021/jm0301437Search in Google Scholar
[2] Kulig K., Sapa J., Maciąg D., Filipek B., Malawska B., Synthesis and pharmacological evaluation of new 1-[3-(4-arylpiperazin-1-yl)-2-hydroxypropyl]-pyrrolidin-2-one derivatives with anti-arrhythmic, hypotensive, and alpha-adrenolytic activity, Arch. Pharm. (Weinheim), 2007, 340, 466–475 http://dx.doi.org/10.1002/ardp.20070003910.1002/ardp.200700039Search in Google Scholar
[3] Ferrarini P.L., Mori C., Badawneh M., Menera C., Saccomanni G., Calderone V., et al., Stereoselective synthesis and βblocking activity of substituted (E)-and (Z)-4(1H)-[1-(3-alkylamino-2-hydroxypropyl)oximino]-2,3-dihydro-1,8-naphthyridine. Potential anti-hypertensive agents. Part VI, Eur. J. Med. Chem., 1997, 32, 955–963 http://dx.doi.org/10.1016/S0223-5234(97)89639-010.1016/S0223-5234(97)89639-0Search in Google Scholar
[4] Bartošova L., Frydrych M., Hulakova G., Berankova K., Strnadova V., Mokry P., et al., Efficacy of newly synthesized 44Bu ultrashort-acting beta-adrenergic antagonist to isoprenaline-induced tachycardia — comparison with esmolol, Acta Vet. Brno, 2004, 73, 171–179 10.2754/avb200473020171Search in Google Scholar
[5] Cecchetti V., Schiaffella F., Tabarrini O., Fravolini A., (1,4-Benzothiazinyloxy)alkylpiperazine derivatives as potential antihypertensive agents, Bioorg. Med. Chem. Lett., 2000, 10, 465–468 http://dx.doi.org/10.1016/S0960-894X(00)00016-010.1016/S0960-894X(00)00016-0Search in Google Scholar
[6] Handzlik J., Maciąg D., Kubacka M., Mogilski Sz., Filipek B., Stadnicka K., et al., Synthesis, alpha 1-adrenoceptor antagonist activity, and SAR study of novel arylpiperazine derivatives of phenytoin, Bioorg. Med. Chem., 2008, 16, 5982–5998 http://dx.doi.org/10.1016/j.bmc.2008.04.05810.1016/j.bmc.2008.04.058Search in Google Scholar
[7] Chiang Ch.-H., Chang T.-J., Lu D.-W., Lee A.-R., Intraocular pressure lower effects of novel arylpiperazine derivatives, J. Ocular Pharmacol. Ther., 1998, 14, 313–322 http://dx.doi.org/10.1089/jop.1998.14.31310.1089/jop.1998.14.313Search in Google Scholar
[8] Caliendo G., Santagada V., Perissutti E., Fiorino F., Derivatives as 5HT1A receptor ligands-past and present, Curr. Med. Chem., 2005, 12, 1721–1753 http://dx.doi.org/10.2174/092986705436722010.2174/0929867054367220Search in Google Scholar
[9] Chilmonczyk Z., Mazgajska M., Iskra-Jopa J., Chojnacka-Wojcik E., Tatarczyńska E., Kłodzirska E., et al., Pharmacological properties and SAR of new 1,4-disubstituted piperazine derivatives with hypnotic-sedative activity, J. Pharm. Pharmacol., 2002, 54, 689–698 http://dx.doi.org/10.1211/002235702177884410.1211/0022357021778844Search in Google Scholar
[10] Di Santo R., Costi R., Artico M., Massa S., Ragno R., Marshall G.R., et al., Pharmacological properties and SAR of new 1,4-disubstituted piperazine derivatives with hypnotic-sedative activity, Bioorg. Med. Chem., 2002, 10, 2511–2526 http://dx.doi.org/10.1016/S0968-0896(02)00119-010.1016/S0968-0896(02)00119-0Search in Google Scholar
[11] Kimura M., Masuda T., Hamada K., Kawakatsu N., Kubota N., Mitani M., et al., Antioxidative activities of novel diphenylalkyl piperazine derivatives with high affinities for the dopamine transporter, Bioorg. Med. Chem. Lett., 2004, 14, 4287–4290 http://dx.doi.org/10.1016/j.bmcl.2004.05.09110.1016/j.bmcl.2004.05.091Search in Google Scholar
[12] Filosa R., Peduto A., de Caprariis P., Saturnino C., Festa M., Petrella A., et al., Synthesis and antiproliferative properties of N3/8-disubstituted 3,8-diazabicyclo[3.2.1]octane analogues of 3,8-bis[2-(3,4,5-trimethoxyphenyl)pyridin-4-yl]methylpiperazine, Eur. J. Med. Chem., 2007, 42, 293–306 http://dx.doi.org/10.1016/j.ejmech.2006.11.01310.1016/j.ejmech.2006.11.013Search in Google Scholar
[13] Shaw Y.-J., Yang Y.-T., Garrison J.B., Kyprianou N., Chen Ch.-S., Pharmacological exploitation of the alpha1-adrenoreceptor antagonist doxazosin to develop a novel class of antitumor agents that block intracellular protein kinase B/Akt activation, J. Med. Chem., 2004, 47, 4453–4462 http://dx.doi.org/10.1021/jm049752k10.1021/jm049752kSearch in Google Scholar
[14] Lombardo L.J., Lee F.Y., Chen P., Norris D., Barrish J.C., Behnia K., et al., Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays, J. Med. Chem., 2004, 47, 6658–6661 http://dx.doi.org/10.1021/jm049486a10.1021/jm049486aSearch in Google Scholar
[15] Stefańska J., Struga M., Tyski S., Kossakowski J., Dobosz M., Antimicrobial activity of 2,4-dihydro-[1,2,4]triazol-3-one derivatives, Pol. J. Microbiol., 2008, 57, 179–182 Search in Google Scholar
[16] Foroumadi A., Emami S., Hassanzadeh A., Rajaee M., Sokhanvar K., Moshafi M.H., et al., Synthesis and antibacterial activity of N-(5-benzylthio-1,3,4-thiadiazol-2-yl) and N-(5-benzylsulfonyl-1,3,4-thiadiazol-2-yl)piperazinyl quinolone derivatives, Bioorg. Med. Chem. Lett., 2005, 15, 4488–4492 http://dx.doi.org/10.1016/j.bmcl.2005.07.01610.1016/j.bmcl.2005.07.016Search in Google Scholar
[17] Richter S., Parolin C., Palumbo M., Palu G., Antiviral properties of quinolone-based drugs, Curr. Drug Target Infect Disord., 2004, 4, 111–116 http://dx.doi.org/10.2174/156800504334092010.2174/1568005043340920Search in Google Scholar
[18] Hadizadeh F., Mehrparvar A., Synthesis of some new 1-[2-(alkylthio-1-benzyl-5-imidazolyl) carbonyl]-4-[3-(isopropylamino)-2-pydridyl] piperazines as anti-HIV, J. Sci. Isl. Rep. Iran., 2004, 15, 131–134 Search in Google Scholar
[19] Pinna G.A., Loriga G., Murineddu G., Grella G., Mura M., Vargiu L., et al., Synthesis and anti-HIV-1 activity of new delavirdine analogues carrying arylpyrrole moieties, Chem. Pharm. Bull., 2001, 49, 1406–1411 http://dx.doi.org/10.1248/cpb.49.140610.1248/cpb.49.1406Search in Google Scholar
[20] Kossakowski J., Wojciechowska A., Synthesis of oxiran-2-ylmethyl and oxiran-2-ylmethoxy derivatives of some 4-azatricyclo[5.2.1.0(2,6)]dec-8-ene-3,5-diones as potential beta-adrenolytics, Acta Pol. Pharm., 2006, 63, 485–490 Search in Google Scholar
[21] Clinical and Laboratory Standards Institute, Performance Standards for Antimicrobial Disc Susceptibility Tests; Approved Standard M2-A9. Clinical and Laboratory Standards Institute, Wayne, PA, USA, 2006 Search in Google Scholar
[22] Clinical and Laboratory Standards Institute, Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard M7-A7. Clinical and Laboratory Standards Institute, Wayne, PA, USA, 2006 Search in Google Scholar
[23] Pauwels R., Balzarini J., Baba M., Snoeck R., Schols D., Herdewijn P., et al., Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds, J. Virol. Meth, 1988, 20, 309–321 http://dx.doi.org/10.1016/0166-0934(88)90134-610.1016/0166-0934(88)90134-6Search in Google Scholar
© 2009 Versita Warsaw
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
